Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab/Ipilimumab Maintenance in Advanced Urothelial Cancer
NCT05219435Phase 2Completed
- Sponsor
- SOGUG
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in urothelial carcinoma (UC), sponsored by SOGUG. Started Jul 2022; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05219435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219435.